Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

E. Campora, A. Vidali, S. Mammoliti, N. Ragni, P. F. Conte

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.

Original languageEnglish
Pages (from-to)181-183
Number of pages3
JournalEuropean Journal of Gynaecological Oncology
Volume11
Issue number3
Publication statusPublished - 1990

Fingerprint

Endometrium
Doxorubicin
Cyclophosphamide
Adenocarcinoma
Endometrial Neoplasms
Therapeutics
Radiotherapy
Hormones
Drug Therapy
Survival

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide. / Campora, E.; Vidali, A.; Mammoliti, S.; Ragni, N.; Conte, P. F.

In: European Journal of Gynaecological Oncology, Vol. 11, No. 3, 1990, p. 181-183.

Research output: Contribution to journalArticle

@article{14cce22e5fcd4612ac031486e370f531,
title = "Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide",
abstract = "Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46{\%}) achieved an objective response: 1 complete response (8{\%}) and 5 partial responses (38{\%}). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.",
author = "E. Campora and A. Vidali and S. Mammoliti and N. Ragni and Conte, {P. F.}",
year = "1990",
language = "English",
volume = "11",
pages = "181--183",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

AU - Campora, E.

AU - Vidali, A.

AU - Mammoliti, S.

AU - Ragni, N.

AU - Conte, P. F.

PY - 1990

Y1 - 1990

N2 - Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.

AB - Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025073788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025073788&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 181

EP - 183

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 3

ER -